Skip to content

Physiological basis underlying antidepressant-induced activation of TrkB receptors

O. Alitalo, S. Kohtala, Marko Rosenholm, Piia Kohtala, Roosa Saarreharju, N. Matsui, Gemma González Hernández, H. Müller, W. Theilmann, M. Sarparanta, A. Klein, O. Kärkkäinen, S. Rozov, T. Rantamäki

bioRxiv August 31, 2021 preprint DOI: 10.1101/2021.08.30.458151 via Semantic Scholar

Summary

AI-generated from the abstract

Both pharmacological and non-pharmacological treatments for depression activate TrkB receptors—a known antidepressant target—by inducing a physiological response linked to sedation. Rapid-acting antidepressants trigger TrkB signaling by evoking a state characterized by electroencephalographic slow-wave activity, behavioral immobility, reduced cerebral glucose utilization, and lowered body temperature. This signaling was not impaired in animals with reduced activity-dependent BDNF release but was diminished by maintaining animals in a warm ambient temperature. Preventing the hypothermic response attenuated the behavioral effects of the rapid-acting antidepressant nitrous oxide. The findings suggest that changes in energy expenditure and thermoregulation are essential, but not sufficient, for antidepressant responses, challenging pharmacology-centric hypotheses and highlighting the role of bioenergetics and thermoregulation.

Study at a glance

Characteristics Observational study
Population Animals
Intervention nitrous oxide
Keywords Biology Medicine
Key finding Antidepressant-induced TrkB signaling is driven by a hypothermic response and changes in energy metabolism, not solely by pharmacological properties.

Abstract

We show that both pharmacological and non-pharmacological treatments of depression activate TrkB receptors—a well-established target of antidepressants—by inducing a physiological response coupled to sedation. Several rapid-acting antidepressants trigger TrkB signaling by evoking a state associated with electroencephalographic slow-wave activity, behavioral immobility, reduced cerebral glucose utilization, and lowered body temperature. Remarkably, antidepressant-induced TrkB signaling was not compromised in animals exhibiting reduced activity-dependent release of BDNF but was diminished by maintaining animals in warm ambient temperature. Most importantly, prevention of the hypothermic response attenuated the behavioral effects produced by rapid-acting antidepressant nitrous oxide. Our results suggest that the phenomenon underlying TrkB transactivation—changes in energy expenditure and thermoregulation—is essential, but not sufficient, for antidepressant responses. Indeed, regardless of differential clinical and pharmacodynamic properties, all drugs that disrupt energy metabolism and induce hypothermia activated TrkB. This study challenges pharmacology-centric hypotheses regarding antidepressant effects and highlight the role of complex changes in bioenergetics and thermoregulation. Highlights Rapid-acting antidepressants evoke homeostatic emergence of slow-wave sleep during which TrkB signaling becomes regulated. Non-antidepressant metabolic inhibitors and diverse sedatives activate TrkB signaling. Reduction in body temperature determined the ability of antidepressants to transactivate TrkB. Drug-induced TrkB signaling was blunted by maintenance of normothermic body temperature. Warm ambient temperature after nitrous oxide exposure blocked the antidepressant-like effects. Graphical abstract

Comments

No comments yet.

Log in to comment